论文部分内容阅读
目的观察老年晚期胃癌患者应用卡培他滨单药治疗的临床效果。方法回顾性分析医院收治的老年晚期胃癌患者43例的临床资料,根据不同的治疗方法进行分组,常规支持治疗患者标记为对照组22例,卡培他滨治疗患者标记为观察组21例,观察比较2组患者治疗效果及生存质量情况(并发症发生情况)。结果观察组治疗有效率为42.86%,生存期为(16.86±4.52)个月;对照组治疗有效率为9.09%,生存期为(11.70±3.44)个月,观察组治疗效果优于对照组(P<0.05);观察组并发症发生率为33.33%,低于对照组的59.09%(P<0.05)。结论口服卡培他滨单药治疗老年晚期胃癌给药简单,治疗后患者胃肠道、手足皮肤的不良反应少,有效控制患者癌细胞扩散,延长患者的生存时间,疗效显著,安全性好。
Objective To observe the clinical effect of capecitabine monotherapy in elderly patients with advanced gastric cancer. Methods The clinical data of 43 patients with advanced gastric cancer admitted to the hospital were retrospectively analyzed. According to the different treatment methods, 22 patients in the routine supportive therapy were marked as control group and 21 as the observation group in capecitabine-treated patients. The treatment effect and quality of life of the two groups were compared (complication occurred). Results The effective rate of observation group was 42.86% and the survival time was (16.86 ± 4.52) months. The effective rate of the control group was 9.09% and the survival time was (11.70 ± 3.44) months. The observation group had better effect than the control group P <0.05). The incidence of complications in the observation group was 33.33%, which was lower than 59.09% in the control group (P <0.05). Conclusion The oral administration of capecitabine monotherapy for the treatment of elderly patients with advanced gastric cancer is simple, after treatment, patients with gastrointestinal tract, hand and foot skin adverse reactions, effectively control the spread of cancer cells in patients with prolonged survival time, significant effect and good safety.